Lonza to double production of Covid-19 vaccine at Swiss plant
Lonza has struggled to recruit enough workers to join its Visp plant, which now has three production lines set up and plans three more by early 2022.
Keystone / Olivier Maire
Swiss biotech firm Lonza will add three more production lines to its site in Visp, southwestern Switzerland, to manufacture an active ingredient for the Moderna vaccine, as part of a larger effort to boost the global supply of doses.
This content was published on
2 minutes
swissinfo.ch/SRF/gw
Español
es
Lonza duplicará la producción de la vacuna COVID-19 en su planta suiza
The new production lines will be added gradually to three existing lines and be fully operational by early 2022, Lonza said on Thursday. The two companies signed a ten-year contract in 2020 that enables Lonza to make a drug substance for the mRNA vaccine at its plant for the global market outside the United States.
In a separate press release, Moderna said it planned to increase the overall supply to up to three billion doses by 2022. The firm calculates there will be greater demand for its vaccine as the need for booster shots is likely to grow starting next year.
The announcement comes as Lonza struggles to recruit enough workers to join its Visp plant. Biotech specialists are currently in high demand worldwide as a result of the pandemic, Swiss public television, SRF, reported, adding that the interior ministry is now actively helping Lonza to find specialists from inside the federal administration and universities, including the federal technology institutes ETH Zurich and the EPFL in Lausanne.
Lonza has reportedly recruited temporary staff from food giant Nestlé with help from the Swiss government. Moderna has blamed projected delays in shipments of the vaccine to markets such as the UK and Canada on production bottlenecks, according to Reuters.
This content was published on
Swiss minister Karin Keller-Sutter wants to use Platform X to communicate with the population during her term as president in 2025.
Swiss Post delivers record number of parcels in pre-Christmas period
This content was published on
Swiss Post delivered a total of 22.3 million parcels between the Black Friday promotional week at the end of November and Christmas.
SWISS plane in Graz: employee still in intensive care
This content was published on
The cabin crew member of the SWISS Airbus A220 which made an emergency landing in Graz, Austria, on Monday is still in intensive care.
WWF sounds alarm: wildlife populations are plummeting
This content was published on
The WWF’s Living Planet Report 2024 found that the wild animal populations surveyed have shrunk by an average of 73% over the last 50 years.
Two decades after tsunami, Swiss tourists flock to Southeast Asia
This content was published on
Twenty years after a catastrophic tsunami in Southeast Asia, the region is again a top destination for Swiss, including at Christmas.
Swiss forests better equipped for storms 25 years after Lothar
This content was published on
Twenty-five years after Hurricane Lothar wreaked havoc in Switzerland, the country’s forests are now better prepared, experts say.
Media: Swiss medical services done abroad are billed at Swiss rates
This content was published on
In Switzerland, some medical services carried out abroad are still billed at Swiss rates, despite costing less, RTS reports.
Swiss firm Lonza to help produce anti-Covid nasal spray in the US
This content was published on
As part of its agreement with American company Altimmune, Lonza will allocate a dedicated manufacturing facility for AdCOVID nasal spray vaccine.
Switzerland mulls future European coordination on medical supplies
This content was published on
“The pandemic has shown us that we are very dependent, maybe too much so, on other markets,” Swiss President Guy Parmelin has said.
Switzerland in race for sufficient Covid immunisation
This content was published on
Health authorities have called for an extra effort from the Swiss population to keep Covid infections as low as possible in the next few months.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.